arbiter
JournalsPricingAccount

External validation of the budget impact analysis of the drug fingolimode in the treatment of multiple sclerosis

Cesar Ricardo Simioni Campello et al.

Cost Effectiveness and Resource Allocation2026https://doi.org/10.1186/s12962-025-00698-6article
ABDC C
Weight
0.50

What the paper says

The validation process of the budget impact analysis of the incorporation of the drug fingolimod in 2017 resulted in savings of around US$ 82,4 million in relation to the value proposed for incorporation.

Open paper page →

Cite this paper

https://doi.org/https://doi.org/10.1186/s12962-025-00698-6

Or copy a formatted citation

@article{cesar2026,
  title        = {{External validation of the budget impact analysis of the drug fingolimode in the treatment of multiple sclerosis}},
  author       = {Cesar Ricardo Simioni Campello et al.},
  journal      = {Cost Effectiveness and Resource Allocation},
  year         = {2026},
  doi          = {https://doi.org/https://doi.org/10.1186/s12962-025-00698-6},
}

Paste directly into BibTeX, Zotero, or your reference manager.

Flag this paper

External validation of the budget impact analysis of the drug fingolimode in the treatment of multiple sclerosis

Flags are reviewed by the Arbiter methodology team within 5 business days.

Evidence weight

0.50

Balanced mode · F 0.40 / M 0.15 / V 0.05 / R 0.40

F · citation impact0.50 × 0.4 = 0.20
M · momentum0.50 × 0.15 = 0.07
V · venue signal0.50 × 0.05 = 0.03
R · text relevance †0.50 × 0.4 = 0.20

† Text relevance is estimated at 0.50 on the detail page — for your query’s actual relevance score, open this paper from a search result.